Siplizumab bei T1DM (DESIGNATE)
Eine T-Zell-Phänotyp-Signatur-gesteuerte Dosisfindungsstudie mit Siplizumab bei Typ-1-Diabetes mellitus (ITN095AI)
This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites.
The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM.
The secondary objectives are to:
- Assess the safety profile of siplizumab in recently diagnosed T1DM.
- Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- University of Colorado School of Medicine: Barbara Davis Center for Diabetes
-
-
Iowa
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes
-
-
New York
-
New York, New York, Vereinigte Staaten, 10032
- Columbia University Medical Center: Naomi Berrie Diabetes Center
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten, 75390
- University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98101
- Benaroya Research Institute at Virginia Mason: Diabetes Research Program
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Ability to provide informed consent (parental permission and informed assent of minor, if applicable).
-
Male or female between 8 to 45 years of age.
-
Diagnosis of T1DM within 18 months (550 days) of enrollment (V0).
-
Positive for at least one diabetes-related autoantibody, including:
- Glutamate decarboxylase (GAD-65),
- Insulin, if obtained within 10 days of the onset of exogenous insulin therapy,
- Insulinoma antigen-2 (IA-2), or
- Zinc transporter-8 (ZnT8).
-
Peak stimulated C-peptide level > 0.15 nmol/L following a MMTT conducted ≥ 21 days from diagnosis and within 37 days of enrollment (V0).
-
Completion of a SARS-CoV-2 vaccination, according to current CDC recommendations and FDA approval(s) or emergency use authorization(s). If the participant requires administration of vaccine(s) to meet eligibility requirements, they must complete the vaccination series at least 2 weeks prior to enrollment (V0).
Exclusion Criteria:
-
1. Use of investigational drugs within 24 weeks of participation with the exception of any vaccine for the prevention of SARS-CoV-2 infection and emergency use authorization medications for treating SARS-CoV-2.
-
Severe reaction or anaphylaxis to humanized monoclonal antibodies.
-
Inability to complete a mixed meal tolerance test:
- History of significant allergy (e.g., anaphylaxis) to milk or soy proteins.
- Inability to disable hybrid closed loop system.
-
History of recent (within 180 days of V0) or ongoing uncontrolled bacterial, viral, fungal or other opportunistic infections, including:
- Human immunodeficiency virus (HIV),
- Current or prior infection with hepatitis B (HBV), as indicated by positive HBsAg or positive HBcAb,
- Current or prior hepatitis C (HCV), unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 12 weeks after cessation of therapy),
- Positive QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests. PPD or T-SPOT®.TB may be substituted for the QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests,
- Active infection with EBV as detected by PCR or serology at the screening visit (V-1),
- Active infection with cytomegalovirus (CMV) as detected by PCR or serology at the screening visit (V-1),
-
Positive molecular testing of SARS-CoV-2 within 30 days of V-1.
-
Any of the following laboratory abnormalities confirmed by repeat tests at least 1 week apart:
- White blood count (WBC) < 3 x 103/μL;,
- CD 3+ CD4+, T cell count below the lower limit of normal,
- Platelet count < 150,000 /μL,
- Hemoglobin < 10 g/dL,
- ALT ≥ 2x upper limit of normal (ULN) or
- AST ≥ 2x ULN
- Serum creatinine >1.5x ULN in adults or >ULN in pediatrics.
- Absolute lymphocyte count (ALC) below the LLN.
-
Prior or current treatment that is known to alter the natural history of T1DM or immunologic status, including high dose inhaled, extensive topical or systemic glucocorticoids.
-
Current or prior (within last 14 days of the V-1 MMTT) use of any medication known to influence glucose tolerance (e.g., atypical antipsychotics, diphenylhydantoin, thiazide, or other potassium-depleting diuretics, β-adrenergic blockers, niacin).
-
Current or prior (within the last 30 days of the V-1 MMTT) use of non-insulin medications to treat insulin resistance or elevated glucose levels.
-
Previous or current diagnosis of malignancy.
-
History of bone marrow transplantation, solid organ transplantation, or primary immunodeficiencies.
-
History or diagnoses of other autoimmune diseases with the exception of stable thyroid or celiac disease.
-
History of significant cardiovascular disease.
-
Vaccination with a live attenuated vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette- Guérin, and smallpox) within 30 days of V0.
-
Women of child-bearing potential who are unwilling to use a medically acceptable form of contraception from 14 days prior to V0 until study Week 52.
-
Women who are pregnant, lactating, or planning on pregnancy during the study.
-
Current, diagnosed mental illness (e.g., severe depression), current diagnosed or self-reported drug, or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
-
Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Adults with T1D 0.08 mg/kg SQ dose
Cohort 1 Group1: 0.08 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
|
Experimental: Adults with T1D 0.12 mg/kg SQ dose
Cohort 1 Group 2: 0.12 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
|
Experimental: Adults with T1D 0.18 mg/kg SQ dose
Cohort 1 Group 3:0.18 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
|
Experimental: Adults with T1D 0.22 mg/kg SQ dose
Cohort 1 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
|
Experimental: Children with T1D 0.08 mg/kg SQ dose
Cohort 2 Group 1:0.08 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
|
Experimental: Children with T1D 0.12 mg/kg SQ dose
Cohort 2 Group 2:0.12 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
|
Experimental: Children with T1D 0.18 mg/kg SQ dose
Cohort 2 Group 3: 0.18 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
|
Experimental: Children with T1D 0.22 mg/kg SQ dose
Cohort 2 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks |
Weekly siplizumab doses for a total of 12 weeks
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants With a T Cell Phenotype Signature Response
Zeitfenster: Week 0 to Week 12
|
A participant is defined as achieving a T Cell phenotype signature response if the participant experiences both a 75% increase or greater from baseline in the CD4 Treg/Tem ratio in blood and a 20% increase or greater from baseline in PD1+TIGIT+ frequency within circulating CD4 Tem. The two criteria will be evaluated at weeks 2, 4, 8, and 12. Both criteria do not need to be achieved at the same time point. |
Week 0 to Week 12
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Frequency of Adverse Events (AEs) in All Siplizumab Dosing Arms
Zeitfenster: From week 0 to week 100
|
AE will include any untoward medical occurrence associated with siplizumab administration or any study-mandated procedure. A treatment-emergent adverse event (TEAE) is defined as in increase in grade from baseline or from the last post-baseline value that doesn't meet grading criteria. |
From week 0 to week 100
|
|
Mixed Meal Tolerance Test (MMTT)-Stimulated Mean 2-hour C-peptide AUC
Zeitfenster: At Weeks 12, 24, 36, 52
|
C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The mixed meal tolerance test (MMTT) was performed in the morning, and blood samples for C-peptide were collected at baseline (pre-meal) and various minutes post-meal at each visit and analyzed by a central laboratory. C-peptide area under the curve (AUC) was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are better in these AUC results: more insulin being produced reflects less severe disease. The mean 2-hour C-peptide AUC, measured in nmol/L, is computed by dividing the total AUC by the length of the MMTT (e.g. 120 minutes). |
At Weeks 12, 24, 36, 52
|
|
Insulin Use (U/kg/Day)
Zeitfenster: At Weeks 6, 12, 24, 36 and 52.
|
Measured as U/kg body weight/day; participants recorded the type and amount of insulin they have used during the 5-day period immediately preceding the beginning of treatment, middle of treatment, end of treatment, and at all follow-up visits |
At Weeks 6, 12, 24, 36 and 52.
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienstuhl: Stephen Gitelman, M.D., University of California San Francisco, School of Medicine: Diabetes Center
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- DAIT ITN095AI
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD-Sharing-Zeitrahmen
On average, within 24 months after database lock for the trial.
IPD-Sharing-Zugriffskriterien
Open access.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .